HKU Pharm.png
careprogramme_logo_02_greenoption.png
English
English
中文

  • Home

  • About Us

  • CARE Programme

    • Study Overview
    • I. Background Incidence
    • II. Active Surveillance
    • III. Record-linkage Study
    • IV. Intensive Monitoring
    • Proposed Protocols

  • FAQ

  • Publication

  • News and Events

  • Contact

  • More

    Use tab to navigate through the menu items.

    • Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a case-control study

    ​

    • Tuberculosis following two-dose SARS-CoV-2 vaccination with messenger RNA vaccine (BNT162b2) and inactivated virus vaccine (CoronaVac): a retrospective cohort study
       

    • Adverse Events of Special Interest and mortality following the mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines
       

    • Two-dose Covid-19 vaccination and possible arthritis flare among patients with rheumatoid arthritis in Hong Kong

    hasan-almasi-nKNm_75lH4g-unsplash Copy.j

    Section Title

    This is a Paragraph. Click on "Edit Text" or double click on the text box to start editing the content and make sure to add any relevant details or information that you want to share with your visitors.

    © 2021. Department of Pharmacology and Pharmacy, The University of Hong Kong. All rights reserved.